Amgen edges up on trial results
The biotech firm edged up 0.6% to 138.69 after reporting positive results from its phase three trial of evolocumab in combination with statins in Japanese patients. Amgen's (AMGN) evolocumab is an injectable cholesterol fighter for patients whose bodies can't tolerate statins such as Pfizer's (PFE) Lipitor. On Thu., Amgen said it had filed an application with U.S. health regulators to sell evolocumab, beating out competitor Regeneron (REGN) to be the 1st to seek approval in the U.S. Regeneron shares fell 0.9% to 346.92. Pfizer shares fell 0.4% to 29.38.
